Core Viewpoint - The company has established a wholly-owned subsidiary in the Qianhai Free Trade Zone, Shenzhen, with a registered capital of up to 22 million yuan, focusing on human genetic diagnosis and treatment technology development [1] Group 1 - The board meeting was held in January 2026 to approve the establishment of the subsidiary [1] - The newly formed subsidiary is named Xinlitai Life Sciences (Shenzhen) Co., Ltd. and has completed its business registration [1] - The legal representative of the subsidiary is Xu Wenjie [1]

Core Viewpoint - The article discusses the performance of the A-share market, highlighting the fluctuations in major indices and the notable movements in specific sectors such as media and pharmaceuticals. Market Performance - The Shanghai Composite Index decreased by 0.02% to 4122.34, while the Shenzhen Component Index also fell by 0.02% to 14206.26. The ChiNext Index dropped by 0.14% to 3328.02, and the Sci-Tech Innovation Board Index rose by 0.19% to 1800.35 [4][12]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.4 trillion yuan, with over 2800 stocks declining [6]. Sector Highlights - The media sector experienced significant gains, with multiple stocks such as Light Media and China Film hitting the daily limit, and Huace Film and Happiness Blue Sea rising over 15% [5][6]. - The innovative drug concept saw a surge, with stocks like Guangsheng Tang increasing by over 13% [6]. - The semiconductor sector also performed well, with stocks like Chipone Technology rising over 8% [10]. New Listings - Three new stocks were listed, with N Electric Technology opening at a remarkable increase of 750.05% on its first day [11]. Other Market Movements - The precious metals, shipping, and liquor sectors showed weakness, contrasting with the strong performance of the media and innovative drug sectors [5][6].

Group 1 - The A-share innovative drug sector is experiencing significant fluctuations and has become a core highlight in the pharmaceutical industry, with companies like Wanbangde and Haixiang Pharmaceutical hitting the daily limit up [1] - Multiple stocks, including Xinlitai and Hansen Pharmaceutical, are rising in tandem, indicating a dual-leader effect and a broader market rally within the sector [1] - Increased market attention and net capital inflow are evident, showcasing a clear upward trend and structural opportunities within the sector [1] Group 2 - A major strategic partnership has been established between Innovent Biologics and Eli Lilly, enhancing confidence in the sector and promoting the globalization of domestic innovative drugs [2] - The industry is projected to experience strong growth, with a significant increase in the number of approved domestic innovative drugs and market size by 2025, alongside record-high overseas licensing transactions [2] - Continuous policy support is evident, with the 2025 version of the medical insurance catalog adding several innovative drugs, addressing implementation challenges and providing a supportive framework for industry development [2] Group 3 - The innovative drug research and development sector is a core beneficiary of policy, technology, and globalization benefits, with companies like Wanbangde and Xinlitai directly benefiting from the industry's growth [3] - The pharmaceutical raw materials and CDMO sectors, represented by Haixiang Pharmaceutical, are also benefiting from the commercialization of innovative drugs, leading to increased demand [3] - The traditional Chinese medicine innovative drug sector is experiencing growth due to industry innovation and policy support, with companies like Hansen Pharmaceutical and Qianjin Pharmaceutical participating in the sector's upward trend [3]

北京市金杜（深圳）律师事务所 关于深圳信立泰药业股份有限公司 2026 年第一次临时股东会 的法律意见书 致：深圳信立泰药业股份有限公司 北京市金杜（深圳）律师事务所（以下简称本所）接受深圳信立泰药业股份有限 公司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委 员会（以下简称中国证监会）《上市公司股东会规则》（以下简称《股东会规则》） 等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香 港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规 章和规范性文件及现行有效的公司章程有关规定，指派律师出席了公司于 2026 年 2 月 6 日召开的 2026 年第一次临时股东会（以下简称本次股东会），并就本次股东会 相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2025 年第一次临时股东大会审议通过的（《深圳信立泰药业股份有限 公司章程》以下简称《公司章程》）； 2. 公司于 2026 年 1 月 22 日刊登于 ...

证券代码：002294 证券简称：信立泰 编号：2026-012 深圳信立泰药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决提案的情况。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本决议所称中小投资者是指单独或合计持有公司 5%以上股份的股东、公 司董事、高级管理人员以外的其他股东。 一、会议召开情况 1、会议召集人：深圳信立泰药业股份有限公司第六届董事会 5、会议主持人：叶宇翔先生。 6、表决方式：现场书面投票表决与网络投票相结合方式 7、《关于召开 2026 年第一次临时股东会的通知》已于 2026 年 1 月 22 日登 载于信息披露媒体《中国证券报》、《证券时报》、巨潮资讯网 www.cninfo.com.cn 及深圳证券交易所网站。 8、本次股东会的召集、召开，符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定。 二、会议出席情况 （一） 股东出席总体情况 2、召开时间： 现场会议时间：2026 年 2 月 6 日 14:3 ...

Group 1 - The core point of the article is that Shenzhen Sinopharm Co., Ltd. announced the release of a portion of its shares from pledge, specifically 43 million shares [1] - As of the announcement date, Sinopharm Co., Ltd. holds approximately 635 million shares, accounting for 56.99% of the total shares of the company [1] - After the release of the pledged shares, the total number of shares still under pledge is 54 million, which represents 8.5% of Sinopharm's total holdings and 4.84% of the company's total shares [1]

证券代码：002294 证券简称：信立泰 编号：2026-011 深圳信立泰药业股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）于近日接到公司控股股东信 立泰药业有限公司（下称"香港信立泰"）的通知，获悉其将所持有的本公司部 分股份解除质押。具体情况如下： | 股东名 | | 是否为控股 股东或第一 | 本次解除质 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | | | 押股份数量 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | | | 大股东及其 一致行动人 | （万股） | 比例 | 比例 | | | | | 信立泰 药业有 | | 控股股东、 第一大股东 | 4,300.00 | 6.77% | 3.86% | 2022-10-10 | 2026-02-02 | 南洋商业银行 有限公司 | | 限公司 | | | | | | | ...

Group 1 - The core point of the article is that the controlling shareholder of the company, Xinlitai Pharmaceutical Co., Ltd., has notified the company about the release of part of its pledged shares, specifically 43 million shares [1] - The related procedures for the release of the pledged shares have been completed at the China Securities Depository and Clearing Corporation [1] - This action may indicate a positive development for the company, as it reflects the controlling shareholder's confidence in the company's future [1]

Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]